Skip to main content
TipRanks
Go Ultimate75% OFF

Bioextrax AB (BIOEX) AI Stock Analysis

0 Followers
SE:BIOEX

Bioextrax AB

(Nasdaq OMX AB:BIOEX)

Select Model
Rating:54Neutral
Price Target:SEK 2.50â–²(0.40% Upside)
Action:upgraded
Date:11/13/26

The overall stock score of 54 reflects a stark contrast between deeply concerning fundamentals and strong technical momentum. The company faces critical financial challenges, including severe cash burn and a lack of profitability, resulting in poor financial and valuation scores. However, the stock currently enjoys robust bullish momentum and trades above all major moving averages, which elevates its short-term technical profile despite the significant long-term fundamental risks.

Positive Factors
Debt-free balance sheetA debt-free balance sheet reduces refinancing exposure and interest obligations, giving Bioextrax greater flexibility while it develops its products. This structure can help preserve strategic options during periods of weak profitability, although ongoing losses still threaten capital strength.
Negative Factors
Very small, declining revenueSmall and declining revenue limits Bioextrax’s ability to absorb operating expenses and demonstrates that commercial scale has not yet been established. Continued contraction would make it harder to fund product development internally and could delay the transition toward a sustainable operating model.

Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)

-20%-10%0%10%20%30%40%50%60%SE:BIOEX+17.67%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 126.87M
Dividend Yield
―
Average Volume (3M)
70.62K
Price to Earnings (P/E)
-5.9
Beta (1Y)
0.85
Revenue Growth
-37.50%
EPS Growth
1.01%
Country
Sweden
Employees
14
Sector
Industrials
Sector Strength
63
Industry
Biotechnology

Bioextrax AB Business Overview & Revenue Model

Company Description

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules...

Bioextrax AB Financial Statement Overview

Summary

Financial performance is extremely weak, reflecting volatile and low revenue, negative gross margins, and accelerating cash burn. Although the company benefits from a completely debt-free balance sheet, persistent net losses and a shrinking equity base pose substantial long-term solvency risks.

Income Statement

12Very Negative

Balance Sheet

48Neutral

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue360.00K757.00K515.00K2.06M395.00K275.76K
Gross Profit-14.84M-16.43M-915.00K718.00K-18.64M-11.29M
EBITDA-14.16M-17.24M-16.18M-20.65M-18.19M-10.18M
Net Income-14.24M-17.70M-17.34M-21.51M-18.67M-10.53M
Balance Sheet
Total Assets14.49M24.73M29.00M22.52M37.92M12.64M
Cash, Cash Equivalents and Short-Term Investments7.39M3.93M17.27M13.40M27.53M8.98M
Total Debt000000
Total Liabilities2.51M3.51M2.94M1.98M6.15M5.14M
Stockholders Equity11.98M21.21M26.06M20.54M31.77M7.50M
Cash Flow
Free Cash Flow-23.61M-26.20M-18.99M-24.41M-24.38M-9.45M
Operating Cash Flow-23.34M-26.05M-18.78M-23.31M-17.60M-8.48M
Investing Cash Flow-277.00K-152.00K-215.00K-1.10M-6.78M-975.13K
Financing Cash Flow12.58M12.86M22.86M10.28M42.94M16.38M

Bioextrax AB Technical Analysis

Technical Analysis SentimentPositive
Last Price2.49

Price Trends

50DMA2.33Positive
100DMA2.40Positive
200DMA2.53Positive

Market Momentum

MACD0.07Negative
RSI63.38Neutral
STOCH75.90Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Positive. The current price of 2.49 is above the 20-day moving average (MA) of 2.32, above the 50-day MA of 2.33, and below the 200-day MA of 2.53, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 63.38 is Neutral, neither overbought nor oversold. The STOCH value of 75.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOEX.

Bioextrax AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

SE:BIOEX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
SE:BIOEXSE:BIOEX54NeutralSEK 126.87M-5.92-116.56%―-37.50%1.01%
SE:NXTCLSE:NXTCL46NeutralSEK 28.63M-0.59-81.23%―-4.02%35.86%
SE:ANNXSE:ANNX44NeutralSEK 78.46M-2.04―――7.33%
SE:SPAGOSE:SPAGO42NeutralSEK 35.77M-1.12-87.37%―-97.52%31.31%
SE:BIOVIC.BSE:BIOVIC.B41NeutralSEK 87.21M-1.22-75.51%―56.06%63.95%
SE:XINTSE:XINT40UnderperformSEK 120.15M-2.38245.07%―-38.46%9.02%

* Industrials Sector Average

Performance Comparison

-50%0%50%100%SE:BIOEXSE:XINTSE:BIOVIC.BSE:NXTCLSE:SPAGOSE:ANNXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:BIOEX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:BIOEXBioextrax AB2.490.3416.03%
SE:XINTXintela AB0.14-0.12-45.31%
SE:BIOVIC.BBiovica International AB Class B0.30-0.23-43.58%
SE:NXTCLNextCell Pharma AB0.24-0.60-70.95%
SE:SPAGOSpago Nanomedical AB0.04-0.06-56.86%
SE:ANNXAnnexin Pharmaceuticals AB9.02-16.00-63.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026